Journal of Immunological Techniques & Infectious Diseases ISSN: 2329-9541

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Seroprevalence of SARS-CoV-2(COVID-19) Antibody among Blood Donors in a Tertiary Care Centre in South India

Introduction: The novel Severe Acute Respiratory Syndrome Virus 2 (SARS-CoV-2), which is responsible Coronavirus disease (COVID-19), spread worldwide from China, causing a pandemic from late December 2019. Due to the high proportion of asymptomatic or mild infections (Approximately 80%), data restricted to laboratory-confirmed cases do not capture the true extent of the spread or burden of the virus, or its infectionfatality ratio. Therefore, serological detection of specific antibodies against SARS-CoV-2 can better estimate the true number of infections. The current study aims to estimate the seroprevalence of SARS-CoV-2 antibodies among the whole blood donors without any prior COVID-19 history or symptoms.

Objective: To determine seroprevalence of SARS-CoV-2 (COVID-19) antibody (IgG and IgM) among asymptomatic healthy blood donors.

Methods: This was a cross sectional study conducted between March and July, 2021 among 300 blood donors without any prior COVID-19 history or symptoms who came to a tertiary care, multispecialty hospital in south India. Any donor who had recently travelled abroad or donors who had received COVID-19 vaccine are excluded from the study. 3 ml venous blood was drawn in EDTA tube from participants and was tested by “Access SARS CoV-2 IgG assay” and “Access SARS CoV-2 IgM assay” by UniCel DxI 800 Immunoassay analyzer (Beckman coulter). The Access SARS CoV-2 IgG assay and the Access SARS Cov-2 IgM assay detect antibodies to the Receptor Binding Domain (RBD) of the Spike Protein. Result was reported as Reactive if Signal/Cut-off (S/CO)>1.0 and non- Reactive if S/CO <1.

Data was collected and entered into excel sheets and was analyzed by using the software SPSS version 25.

Results: A total of 300 healthy blood donors were included. The study reported seroprevalence of 15.3% for IgG and 4.3% for IgM (95%CI) among asymptomatic whole blood donors. No significant difference was observed across age groups, diet, BMI, ABO/Rh blood type or Ayurveda/homeo immune medicine intake with respect to IgG and IgM reactivity.

Conclusion: 15% of blood donors were seroconverted for COVID-19 during second wave. This is a reflection of widespread seroprevalence in the adult population. Real-time seroprevalence studies will help to know the herd immunity among the blood donors which will assist in knowing the COVID-19 transmission dynamics and distribution of immunity levels at a particular point in time.

Special Features

Full Text

View

Track Your Manuscript

Media Partners

GET THE APP